Morgan Stanley downgraded Fulcrum Therapeutics (NASDAQ: FULC) to Equalweight from Overweight and cut its price target to $8.00 from $27.00.Shares ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE